LLY - ELI LILLY & Co
Close
914.52
0 0%
Share volume: 1,158,803
Last Updated: Tue 24 Dec 2024 06:00:46 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.51%
PREVIOUS CLOSE
CHG
CHG%
$914.52
-120.09
0.15%
Fundamental analysis
71%
Profitability
90%
Dept financing
25%
Liquidity
50%
Performance
70%
Performance
5 Days
5.11%
1 Month
5.47%
3 Months
-13.86%
6 Months
-10.54%
1 Year
39.60%
2 Year
116.44%
Key data
Stock price
$914.52
DAY RANGE
$787.50 - $797.61
52 WEEK RANGE
$583.68 - $972.53
52 WEEK CHANGE
$39.53
DIVIDEND
$1.30
EX-DIVIDEND DATE
08/15/2024
NEXT EARNINGS DATE
10/30/2024
Company detail
CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: lilly.com
Employees: 39,000
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax
Recent news